TRIO Pharmaceuticals, Inc.

About TRIO Pharmaceuticals, Inc.

TRIO Pharmaceuticals is a biotechnology company focused on developing novel dual-targeting antibody drugs to treat cancer by reducing toxicity and enhancing immune response, aiming to provide effective treatments with minimal side effects and improve patient well-being.

Products & Services

TIE-ADC™ (Tumor Immunity Enhancing Antibody-Drug Conjugate™):A dual-targeting ADC designed to kill cancer cells and immunosuppressor cells, removing tumor burden and immunosuppression to enable effective immune attacks against tumors. Targets cancers like TNBC and NSCLC.

TRAILBody™:An antibody drug designed to directly kill cancer cells with no toxicity by activating endogenous cell death, sparing normal cells. Targets cancers like AML, MDS, ovarian, and endometrial cancer.

Specialties

Dual-targeting antibody drugs Cancer immunotherapy Antibody-Drug Conjugates (ADC) Tumor immunosuppression solutions Toxicity-free cancer treatments

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Pre-Series A T: - FT: Pre-Series A	A: 3100000 MR: - FA: 3.1 million FAN: 3100000	D: 2024-12-03 FD: 2024-12-03	4 investors

Pre-Series A Latest

2024-12-03

$3.1M

4 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

P

Patrick Doyle

CEO

LinkedIn (Pro only)

S

Shiva Bhowmik

CSO + Founder

LinkedIn (Pro only)

H

H. Kim Lyerly

CMO + Founder

LinkedIn (Pro only)

W

William Brady

Director of Biotherapeutics

J

Jeffrey Friedman

Board Member + Investor

S

Stephanie Oestreich

Investor + Board Member

View 11 more team members with Pro

Unlock Full Team Directory

Recent News